Heatwurx (PCSA) Projected to Announce Quarterly Earnings on Thursday

Heatwurx (NASDAQ:PCSA) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($1.50) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Heatwurx Price Performance

Shares of NASDAQ:PCSA opened at $2.88 on Thursday. Heatwurx has a one year low of $1.76 and a one year high of $19.64. The firm has a market capitalization of $6.53 million, a price-to-earnings ratio of -0.08 and a beta of 1.05. The company’s fifty day moving average price is $2.77 and its 200-day moving average price is $5.09.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Wall Street Zen cut Heatwurx from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Heatwurx in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $25.00.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.